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The Portuguese Oncology Institute of Lisbon Francisco Gentil (IPOLFG) is a public oncology hospital, located in Lisbon, with a leading
position in the Portuguese oncology medical services, including outpatient (consultations, day hospital, surgeries, complementary means of
diagnosis and therapy) and inpatient services (surgeries and medical internment). It has more than 1800 employees and also develops
research activities.
IPOLFG is a corporate public entity, with the Portuguese State being its only equity holder, and it cannot have interest-bearing debt.
Moreover, 94% of its revenues comes from the Central Administration of the Health System (ACSS), via production and prices stablished on
contract-programs. In 2017, IPOLFG had €131M in revenues, an EBITDA of - €5.4M and FCF of - €12M.
Given the need for extra capacity and better infrastructures, IPOLFG planned an expansion project that consists in constructing a new
building (estimated to start operating in 2022) to concentrate ambulatory medical services (except radiotherapy). The construction, in an
available piece of land at IPOLFG’s campus, of this building with 6 floors above the ground and 4 below (including parking area) is
estimated to require a €40M investment and additional €5M in basic equipment. According to the financing plan, SUCH (a non-profit
private organization of public utility) will invest €12M (receiving the right to exploit IPOLFG’s parking business), Jerónimo Martins will
contribute with €3M and pharmaceutical sponsors with €5M, leaving a remaining amount of €25M for the Portuguese State to invest via
IPOLFG’s statutory capital increase.
The goal of this report is to analyze the financial implications and financial viability of the project, thus giving the relevant financial
information necessary for the competent authorities to have an informed decision. Although some non-financial considerations are made,
those are admittedly out of the scope of this report.
The project’s financial impact for IPOLFG is measured by the NPV, calculated as the difference between the present value (PV) of IPOLFG’s
estimated FCF with the project and the PV of the FCF without the project. A 4.73% discount rate was considered, corresponding to
IPOLFG’s estimated unlevered cost of equity. In the DCF model built, the number of standard patients was used as the core driver to
estimate impacts on revenues and costs via changes in quantities.
2Executive Summary
Page 2 of 2
For the case without the new building, a constant number of standard patients was assumed from 2019 onwards, since IPOLFG is currently
operating near full capacity; thus, revenues and costs are forecasted to grow at the inflation rate. Mainly due to IPOLFG’s negative EBITDA
margin (€141M revenues and €142.2M operating costs in 2021), the negative Operating Cash Flow (OCF) is about - €0.2M per year.
Considering CAPEX equal to depreciation from 2020 onwards and dealing with NWC requirements, annual FCF is about - €6.7M,
corresponding to a PV for IPOLFG’s FCF without the new building of - €141.6M.
For the case of implementing the project, 3 main effects were considered: (i) a 15% increase in the number of standard patients, due to
capacity increase; the respective impacts on revenues and costs were obtained using the number of standard patients as driver; (ii) costs
savings around €1.3M, reflecting higher efficiency, the end of containers renting and in-house production of some services currently
outsourced due to lack of capacity; (iii) a €2M increase in research financing (due to the new building’s Research Center) approximately
matched with an increase in research expenses. Consequently, due to the new building’s shift, revenues are expected to rise 13.3% from
€141M in 2021 to €159.8M in 2023, while costs are forecasted to increase 13.5% from €142.2M in 2021 to €161.8M in 2023. From 2024
onwards, quantities are assumed to increase at the annual growth rate of cancer incident cases in Portugal (~1%) and prices at inflation
(~2%). In this context, the OCF will deteriorate to - €0.8M. The required €45M growth CAPEX is split 20% in 2019, 40% in 2020 and 40%
in 2021. After considering the extra sources of financing, the State should split the €25M equity increase in €8M in 2020 and €17M in
2021. After those initial years characterized by large investments, and a period of 5 years for which it is assumed that the new building
does not require maintenance CAPEX, IPOLFG’s annual FCF is expected to be about - €8.7M. This leads to a PV for IPOLFG’s FCF with the
new building of - €198.4M.
Therefore, the project’s NPV is - €56.7M, the difference between the PV for each case, while the NPV per standard patient (considering a
time-horizon only until 2030) is estimated to be - €550. Thus, the competent authorities are advised to weigh the financial costs of
IPOLFG’s new building with the social welfare benefits – more patients treated by the National Health Service (NHS), higher quality,
reduced waiting lists, among others. Despite the negative NPV, the State may want to approve the project, given the increase in social
welfare. It requires the State to invest additional €550 in equity in IPOLFG for each additional patient treated by the NHS at IPOLFG.
Ultimately, it is a political decision, that may imply, for instance, spending more money in health and less in education.
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Geographic Presence Areas of ActivityHistory Highlights
– The Institute is founded in Lisbon,
with the name Portuguese Institute for
the Study of Cancer, under the tutelage
of the Ministry of Public Instruction.
Professor Francisco Gentil, the main
mentor of the project, is one of the
founders.
– First building, in the current location of
the Institute. Start of the activities.
During the following decades, several
renovations and expansions with extra
buildings at the same location take
place.
– The Institute starts being under the
Ministry of Health tutelage.
– The Institute changes its legal status for
the current one, corporate public entity,
under the name Portuguese Oncology
Institute of Lisbon Francisco Gentil,
Corporate Public Entity (IPOLFG, EPE).
– Medical services in the oncology area
is the current main focus of the Institute,
including: prevention, diagnosis,
treatment, medical care and
rehabilitation.
IPOLFG is the leading oncology hospital
in Portugal, being organized in different
medical areas:
▪ Outpatient / Ambulatory medicine
(consultations; day hospital;
surgeries; complementary means of
diagnosis and therapy, including
chemotherapy and radiotherapy).
▪ Inpatient medicine (surgeries and
medical internment).
– Research and Education:
Oncology research and teaching continue
to be part of the Institute’s activities,
faithful to its origins. Nonetheless, the
resources currently allocated to this area
are few.
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IPOLFG is a public oncology hospital, located in Lisbon, with a leading position in 
Portuguese oncology medical services, both outpatient and inpatient
1.1. IPOLFG’s overview
IPOLFG’s location
IPOLFG’s influence 
area
IPOLFG’s area of intervention. Source: IPOLFG website
Despite the current existence of 3 public
specialized oncology hospitals (Lisbon,
Coimbra, Oporto), IPOLFG continues to have
a paramount position in the national
territory. The designated area of
intervention (which is not limitative)
includes all the regions to the south of
Coimbra, as well as Azores and Madeira
Islands, corresponding to a population of
~4M inhabitants.
1923
1927
1987
2005
The entity being studied (IPOLFG) refers only to the
Portuguese Oncology Institute in Lisbon. Separate
branches of the Institute were created in Coimbra and
Oporto, in 1967 and 1974, respectively.
(1)
(1)
Source: IPOLFG
The key figures of IPOLFG’s operations in 2017 illustrate its dimension and the variety of its services
€131M
- €0.8M
Revenues
EBITDA
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In 2017, IPOLFG’s resources allowed to provide medical services to +52k standard 
patients, yielding negative FCF of - €12M 
As a public hospital, most of IPOLFG’s
revenues are determined by the
government budget (later developed).
Revenues are not enough to offset cost
of sales, personnel costs, supplies and
services expenses.
- €5.4M Net income
IPOLFG has been accumulating losses
every period, registering negative
retained earnings of - €75M in 2017.
IPOLFG’s key financial indicators in 2017 culminate into negative FCF, compensated by the investment of more equity
1.1. IPOLFG’s overview
€5.7M
- €12M
CAPEX
Free Cash 
Flow (FCF)
Both growth CAPEX (later
developed) and maintenance
investments.
The FCF generated for the period
was largely negative. Since cash and
cash equivalents remained
approximately constant, an equity
adjustment through a capital
increase of €12M was necessary.
15 
buildings
Campus 
with 
60,000 m2
287 beds 
inpatients
171 beds 
outpatients
352
541
225
402
183
168
Doctors
Nurses
Technical Assistants
Operational Assistants
Technical Personnel for
Diagnosis and Therapy
Others
1871 
employees Number of employees per type.
Source: IPOLFG 2017 Annual Report
+ 227k consultations
+ 10k inpatients treated
+ 24k outpatients DRG*
+ 64k radiotherapy sessions
52,386 Standard Patients: Given the
variety and complexity of the services
rendered by a hospital, it is commonly
used a standardized figure to allow for
quantities comparisons. The details are
later explained.
Others
* DRG: Diagnosis Related Groups
Source: IPOLFG 2017 Annual Report
7Sources of FinancingSources of Revenues
NHS* revenues:
– Being a public hospital, the services are almost free for the patients (who just have
to pay small moderating fees). Thus, 94% of IPOLFG’s revenues comes from ACSS.**
– The amount received each year is defined in a triannual contract-program, with
annual addenda. This amount depends: on the production quantities predicted for
each service (consultations, surgeries, etc.); on a standard reference price; and on
the case-mix index (CMI).
▪ The standard reference price is the reference for activities grouped and
codified into Diagnosis Related Groups (DRG) and has remained stable in the last
years (€2285 since 2015). Specific activities may have an adjustment factor
applied to the reference price.
▪ The CMI reflects the hospital’s services level of complexity, being also an
adjustment factor applied to the reference price.
– IPOLFG cannot have
any interest-bearing
debt.
– The main source of
debt is accounts
payable to suppliers
(€50M), followed by
advances from
customers (€20M).
1.1. IPOLFG’s overview
The Portuguese State is the only IPOLFG’s equity holder and it is also responsible 
for almost all its revenues, which are defined via ACSS contract-program
123.5
2.7 5.2
IPOLFG’s revenues
in 2017 (m€)
NHS
Non-NHS
Other Op.
Income
Assets
€161M
Short-
term 
Debt
€104M
Equity
€57M
– The Portuguese State is the only equity holder.
– IPOLFG accounts are integrated in the
government budget.
– Every time IPOLFG has negative FCF, having not
enough sources to face the loss of the period, the
State has to invest more capital into IPOLFG.
Non-NHS revenues: include healthcare
subsystems (e.g.: SAMS; CGD) and
moderating fees.
Other operating income: ACSS specific
programs; financing for research
activities; own sources of income (e.g.:
parking fees).
** ACSS (Central Administration of the Health System) is a 
public institute under the tutelage of the Ministry of Health.
The government budget for healthcare in 2017 was €9800M 
(source: ACSS).Source: IPOLFG 2017 
Annual Report
IPOLFG’s Balance Sheet in 2017
Source: IPOLFG 2017 Annual Report
* NHS: National Health Service (SNS in Portuguese).
8Revenues (m€) in 2017
1.2. Benchmarking
IPOLFG’s negative EBITDA follows the general tendency of Portuguese public 
hospitals, reflecting the insufficient income received via ACSS contract-programs
EBITDA (m€) in 2017
– IPOLFG, as well as IPO Porto and IPO Coimbra,
specializes itself in a particular medical area: oncology.
– Not surprisingly, some non-specialized Portuguese public
hospitals have larger annual turnovers. Nonetheless,
IPOLFG and IPO Porto have considerable dimensions.
– Luz Saúde, SA, a private hospital, is the only publicly
traded Portuguese hospital and has a larger turnover.
131 124
49
IPOLFG IPO Porto IPO
Coimbra
430 433
329
273
484
CHU
Lisboa N.
CHU
Coimbra
CHU S.
João
CHU
Porto
Luz
Saúde, SA
-0.8 -0.97
-5.2
IPOLFG IPO Porto IPO
Coimbra
15.6
-27.4 -23.7 -30.9
53.7
CHU
Lisboa N.
CHU
Coimbra
CHU S.
João
CHU
Porto
Luz
Saúde, SA
– The 3 oncology hospitals have all negative EBITDA,
with IPOLFG having the best performance.
– Negative EBITDA is also common among non-
specialized Portuguese public hospitals, being CHU
Lisboa Norte an exception (3.5% EBITDA margin).
– On the other hand, Luz Saúde, SA shows a satisfactory
11% EBITDA margin.
– While private hospitals aim to maximize their profits and
set their own prices, public hospitals receive money via
ACSS contract-programs with the goal of covering their
expenses (which is not achieved in most cases).
▪ Public specialized oncology hospitals (besides IPOLFG)
▪ Some examples of non-specialized public hospitals 
▪ Non-specialized private hospital (publicly traded)
Source: Portal do Benchmark; Luz Saúde, SA 2017 Annual Report
Current situation of IPOLFG’s infrastructures
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The construction of a new building for outpatient medicine is required, since 
current infrastructures are no longer able to respond to capacity and quality needs
1.3. Project’s overview
– Given the increasing demand for IPOLFG’s medical services, it has adopted ad
hoc solutions, with adaptations, small expansions and temporary buildings.
– The current necessity for extra capacity for the ambulatory area can no
longer be satisfied with the existent resources nor with minor adjustments.
– One of the buildings currently used by IPOLFG belongs to the Ministry of
Finance and should be released.
– There are containers holding part of the hospital services (namely
chemotherapy). These temporary solutions must come to an end, given the
lack of sustainability and quality that they imply.
– This dispersion implies the inefficient use of human and technical
resources.
– Patients may have to move from one building to the other, sometimes with
adverse weather conditions. In more critical situations, IPOLFG needs to use
ambulances to transport those patients, supporting the inherent costs.
Need for more 
capacity 
(outpatient 
medicine)
Temporary 
buildings
Outpatient 
medical 
services spread 
over different 
buildings
Problems 
identified since 
the 90s but not 
yet solved
– In several occasions, a construction of a new building was plan to solve
the mentioned problems (e.g.: tender process in 1993; architectural project in
2001; announcement, in 2009, of plans for a new building in Chelas).
– However, projects were always delayed and never went through.
Project for the 
construction of a large 
new building
– Outpatient medicine: the 
new building will concentrate 
almost all the outpatient 
medical area (with the 
exception of radiotherapy), 
currently spread over 
different buildings. It includes:
▪ Medical consultations
▪ Day hospital
▪ Outpatients DRG (namely 
ambulatory surgeries and 
complementary means of 
diagnosis and therapy)
– Research: the new building 
will have a Research Center 
with ~2000 m2, since current 
research infrastructures are 
insufficient (~450 m2).
Source: IPOLFG
Project investment estimated by IPOLFG: €45M
Project goalsProject details
– Capacity increase: immediate shift of 15% in the capacity for
outpatient medical services (but with potential to
accommodate more than 20% capacity increase). This will
allow to:
▪ Reduce the existent waiting lists
▪ Stop sending patients for other hospitals due to
IPOLFG’s lack of capacity
▪ Receive more patients who currently go to non-
specialized hospitals (either public or private)
– Efficiency and quality gains:
▪ Modern infrastructures (substituting containers and
other precarious conditions) will increase the services
quality, with a better allocation of human and technical
resources.
▪ Nearly Zero Energy Building (NZEB): considerable
energy savings thanks to renewable energies (solar
panels); thermal insulation; efficient heating and
ventilation systems.
– Reorganization of current infrastructures, with the
previously explained release of temporary structures,
implying savings with containers rents.
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The new building, requiring a total investment of €45M, will allow to increase 
outpatient capacity (+15%), efficiency, quality and to reorganize infrastructures
1.3. Project’s overview
– Location: available piece of land in IPOLFG’s campus, next to Praça de
Espanha.
– Building features:
▪ Deployment area: ~6k m2
▪ Above ground: ~24k m2 of gross building area; 5 floors for
outpatient medicine and 1 for research
▪ Below ground: ~24k m2 of gross building area; 4 floors for
technical areas and parking
– Timing: after the project and the financing plan approval and the
public procurement of the work, the construction takes about 2 years.
For the analyses conducted, the building is assumed to be constructed
in 2020 and 2021 and start operating in 2022.
– Building (€40M): it comprises the 6 floors above ground (~€28M)
and the 4 floors below ground (~€12M).
▪ The 4 floors below ground include the parking area, which will
have between 800 and 1000 parking spaces.
– Basic Equipment (€5M): although the existent equipment for
outpatient medicine will be used in the new building, some new
medical equipment will need to be bought given the capacity increase.
Source: IPOLFG
Project financing plan
11
The project is going to be partially financed by SUCH (€12M), JMT (€3M) and 
sponsors (€5M); additional €25M are needed via an increase in statutory capital
1.3. Project’s overview
Building
€40M
SUCH
€12M
Sponsors: €5M
Equipment: €5M
JMT: €3M
Statutory Capital 
Increase
€25M
Uses of funds Sources of funds
Representation, not at scale, of the project’s
investment and financing amounts.
– SUCH (€12M): SUCH (Serviço de Utilização Comum dos Hospitais) is a non-profit
private organization of public utility that provides services in the health sector.
IPOLFG and SUCH already signed a protocol:
▪ SUCH commits itself to construct the 4 underground floors (including
technical areas and parking), supporting the inherent investment expenses
(estimated in €12M).
▪ SUCH will bear the implied risk. In particular, if the construction costs more
than €12M, SUCH will support that cost.
▪ The construction must be completed in 12 to 18 months since the starting date.
▪ SUCH will exploit IPOLFG’s parking business, receiving the inherent
revenues. Nonetheless, SUCH commits to pay to IPOLFG the maximum between
€200k per year and 10% of the annual gross revenue (these revenues CFs for
IPOLFG have no incremental impact, since they are approximately equal to the ones
IPOLFG currently receives, i.e., parking revenues have no effect on the project’s valuation).
– Jerónimo Martins [JMT] (€3M): the Portuguese retailing group will construct new
headquarters next to IPOLFG’s campus. It is foreseen, based on negotiations
between IPOLFG, JMT and Lisbon Municipality, that JMT will pay €3M to IPOLFG in
order to use part of IPOLFG’s parking area. However, no protocol was signed yet.
– Sponsors (€5M): based on negotiations between IPOLFG and pharmaceutical
companies with oncology research activities in Portugal, IPOLFG expects they will
contribute with €5M for the research center in the new building. Still uncertain.
– Statutory Capital Increase (€25M): the remaining part of the investment needs
to be financed by the Portuguese State, IPOLFG’s equity holder, since IPOLFG does
not have internal funds to finance the project.
IPOLFG is requiring to the Portuguese State,
via ACSS:
– The approval of the project, since the
investment amount is larger than 2% of the
statutory capital.
– A statutory capital increase of €25M.
Consequently, IPOLFG has to present to the
Ministry of Health and to the Ministry of Finance
a financial analysis about the viability of the
project and the implied results.
Source: IPOLFG
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2. IPOLFG’s value with the project 3. Project’s Net Present Value (NPV)1. IPOLFG’s value without the project
– Carefully analyze IPOLFG current
situation and historical financial
statements: balance sheet, income
statement and cash-flows statement.
– Understand the business model,
different segments and main drivers.
▪ The number of standard patients
was the core driver chosen (later
explained)
– Build a discounted cash-flows (DCF)
model that integrates the 3 Financial
Statements and the identified drivers,
estimating IPOLFG’s future FCF if the
identified project was not implemented.
– Estimate IPOLFG’s cost of capital to use
as the FCF discount rate.
– Obtain IPOLFG’s expected value without
the project as the present value (PV) of
future FCF.
– Calculate the project’s NPV as the
difference between IPOLFG’s value with
the project and IPOLFG’s value without
the project, since it represents the
project’s net incremental financial impact.
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The project’s NPV for IPOLFG is going to be calculated as the difference between 
the expected value with the project and the expected value without the project
2. Methodology
– Using the financial model built,
incorporate the impacts of the project,
namely:
▪ Required investment
▪ Increased revenues and costs that
result from the increased capacity
(outpatient medicine)
▪ Savings (costs reduction) that result
from higher efficiency and
infrastructures reorganization
▪ Increased income received for
research activities and increased
costs
– Apply the Adjusted Present Value
(APV) method, including de additional
impact of the financing effects and using
different discount rates.
– Obtain IPOLFG’s expected value with the
project as the sum of the PV of future FCF
without the financing effects and the PV
of the financing effects.
Important Note: The goal of this report is to
analyze the financial implications and
financial viability of the identified project, as
required by IPOLFG to Nova SBE, thus giving
the relevant financial information necessary
for the competent authorities to have an
informed decision. Although some non-
financial considerations are made (since a
public project in the health sector has to be
analyzed in the context of the social welfare
generated), those are admittedly out of the
scope of this report. Moreover, the financial
analysis is made from IPOLFG’s perspective
(i.e., the NPV for IPOLFG) and not from the
Portuguese State’s.
Question to be addressed: What is the net incremental financial impact for IPOLFG of the new building project?
Methodology:
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Number of standard patients rationale
3. IPOLFG’s value without the project
The proxy number of standard patients is the key driver used to estimate IPOLFG’s 
revenues and costs; it is assumed to remain constant without the new building
Historical 
data source: 
ACSS
– IPOLFG, as hospitals in general, provides a wide variety of services
(medical consultations, nursing consultations, methods of diagnosis,
different types of surgeries, radiotherapy, chemotherapy, etc.), each of
them with its own quantities, prices and different types of costs.
– Given this diversity and complexity, it is unreasonable to analyze and
estimate each specific service separately. One commonly used
approximation (namely by ACSS) is the number of standard
patients. A standard patient is a fictional figure whose idea is basically
to standardize quantities based on the reference price stablished on
ACSS contract-programs for inpatient and outpatient DRG.
– Thus, for a reference price of €2285, to provide one service with a price
of €2285 (as a typical inpatient surgery) corresponds, in quantity
terms, to one standard patient. On the other hand, a consultation with a
price of €100 corresponds to 100/2285 = 0.044 standard patients.
– Revenues for each area are obtained multiplying the number of
standard patients by the reference price.
– Regarding each type of cost (cost of sales, personnel, miscellaneous),
the cost per standard patient was calculated using historical data
(dividing the total costs by the number of standard patients) and then
used to estimate future costs based on quantities evolution.
– Reference price: although constant between 2015 and 2018
(€2285), it is assumed to grow at the inflation rate from
2019 onwards.
– Number of standard patients: expected to close 2018 with
levels similar to 2016. Without the new building, it is
assumed to remain constant from 2019 onwards, since
IPOLFG is near full capacity.
It is important to mention that, although the number of standard
patients decreased 2% in 2017, NHS revenues rose due to an increase
of €4.6M in the addendum value (which has the goal of compensate
production in excess of the contracted one), which suggests that, in
2016, IPOLFG was not compensated by a significant part of the
standard patients (~3.5k).
Sources: ACSS, IMF
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Breakdown (m€) of revenues in 2017 (€131M)
3. IPOLFG’s value without the project
With €53.1M, outpatient medical services represent 40% of IPOLFG’s revenues; 
analyses will focus on the areas that would be affected by the new building
32.4
53.1
15.6
16
6.4
2.7 5.2NHS Inpatient
NHS Outpatient
NHS Oncology Pathologies
NHS Addendum
NHS Others
Non-NHS
Other Op. Income
– As already stated, 94% of IPOLFG’s revenues corresponds to NHS revenues,
received via ACSS contract-program.
– Inside NHS revenues (€123.5M in 2017), outpatient area (€53.1M) has the
largest proportion (43%), including:
▪ NHS Consultations (€23.3M)
▪ NHS Outpatient DRG (€13.M)
▪ NHS Day Hospital (€1.8M)
▪ NHS Radiotherapy (€14.2M)
– The new building is directed precisely for the outpatient area, with the
exception of radiotherapy, which will continue in a separate building.
– In the next page, a detailed analysis is dedicated to the historical evolution of
the areas for which it is required the new building.
NHS Inpatient
With a significant proportion of NHS revenues (26%), it
is far more profitable than the outpatient area (page 26).
Stable in the last years: €33.3M in 2018 vs. €32.5M in
2013.
NHS 
Radiotherapy 
(outpatient)
One of the areas that grew the most in the last years. It
almost double from 2013 (€7.9M) to 2018 (€15.1M).
Specific investments have been made and it does not
require a new building.
NHS Oncology 
Pathologies
The substantial growth from 2013
(€6.3M) to 2016 (€16.3) has now stop,
with predictions of €13.5M for 2018,
followed by a stable path.
NHS Others
Mainly incentives to achieve same
efficiency and quality KPIs. Relatively
stable in the last years, with 2017 levels
equaling 2014 ones (€6.4M).
Areas not affected by the new building:
As mentioned in the last page, the number of standard patients without the new building was assumed to be constant from 2019 onwards.
Although radiotherapy may continue to grow, it is not affected by the new building, so the net incremental impact of that neglection is zero for
effects of the project’s valuation.
Source: 
IPOLFG 2017
Annual Report
Source: IPOLFG
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Breakdown of the sources of revenues (m€) that would 
be affected by the project (2014-2023)
Other Op. Income Non-NHS NHS addendum
NHS Day Hospital NHS Outpatient DRG NHS Consultations
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3. IPOLFG’s value without the project
After a 3.7% CAGR in the last 5 years, ambulatory NHS (excl. radio), NHS addenda, 
non-NHS and other op. income are expected to have a 2% CAGR for the next 5 years
NHS Consultations: (i) Main source of revenue inside ambulatory
area; (ii) 2018 estimated to close at 2014 levels; (iii) Suggests need
for extra capacity.
NHS Outpatient DRG: (i) Relatively constant since 2014; (ii)
Potential to increase with extra capacity.
NHS Day Hospital: (i) Smaller area, but grew ~50% from 2015 to
2018; (ii) Potential to further increase with extra capacity.
NHS Addendum: (i) ACSS defines the contracted production via
contract-programs and remunerates only for that agreed amount,
although IPOLFG cannot deny patients; (ii) Extra production is
usually compensated via contract-programs addenda; (iii) Addenda
values have increased, reflecting the concern to fairly compensate
extra production.
Non-NHS: (i) Patients from Azores and Madeira Islands, previously
considered as Non-NHS, were integrated in NHS in 2015, explaining
the followed declined; (ii) Potential to increase with extra capacity.
Other Op. Income: (i) smaller financing of research activities in
2018 (€0.86M) compared to 2017 (€1.12M); (ii) expected to
increase with Research Center in new building.
Historical 
data source: 
IPOLFG 
Annual 
Reports
As mentioned on slide 15, without the new building, from
2019 onwards, quantities are assumed to remain constant
and prices to rise at the inflation rate.
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3. IPOLFG’s value without the project
Cost of sales per standard patient was the main driver of a 5.6% CAGR in 2014-17. 
Given its expected slowdown, it is forecasted a 2% CAGR for the next years
34 41
46 49 51 52 53 54 55 56
28 25
28 28 28
29 29 30 30 31
50 51
53 55
55 56 57
58 59 61
112 116
126 132
134 137 139
142 145 148
2014 2015 2016 2017 2018E 2019F 2020F 2021F 2022F 2023F
Cost of sales Miscellaneous Personnel
675 
800 
860 
934 950 965 
982 1,001 1,022 
1,044 
549 
488 518 
532 521 530 539 549 561 
573 
981 987 988 
1,050 1,026 1,042 1,061 
1,081 1,104 1,127 
2014 2015 2016 2017 2018E 2019F 2020F 2021F 2022F 2023F
Cost of sales Miscellaneous Personnel
Costs (m€) breakdown per type, 2014-2023Costs per standard patient (€), 2014-2023
– Between 2014 and 2017, operating costs (CAGR of 5.4%) grew
slightly more than operating revenues (CAGR of 4.9%).
– Personnel costs are the largest ones, but cost of sales have grown
the most.
– Forecasting: with constant quantities, the growth is explained by
higher costs per standard patient (left box).
– While personnel and miscellaneous costs per standard patient
have been relatively stable, cost of sales per standard patient have
been growing substantially due to increased expenses with
medicines and pharmaceutical products.
– Forecasting: costs per standard patient are assumed to grow at
the inflation rate (even for cost of sales, 2018 data already suggests
a slowdown of the previous escalation; it is believed the growth
will indeed slowdown thanks to generic drugs increased usage).
Historical data source: IPOLFG Annual Reports. Note: while 2018 revenues
have a higher precision, given ACSS contract-programs, 2018 costs’ estimations
may not exactly correspond to end-of-the-year values.
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3. IPOLFG’s value without the project
Based on negative EBITDA margins and precaution regarding non-recurrent 
income, OCF is forecasted to be slightly negative, about - €0.2M per year
Revenues and operating expenses summarize the analyses
previously done.
IPOLFG’s EBITDA has been slightly negative and is expected to
continue to be, reflecting that the prices stablished on ACSS
contract-programs are not enough to cover operational costs.
IPOLFG has substantial D&A expenses due to the high level of
fixed assets (mainly buildings and basic equipment). Slight
increase due to recent additional CAPEX is expected to stop in the
scenario without the expansion.
Financial gains and losses are not material.
Non-recurrent income (mainly subsidies recognized as income
when acquired goods are amortized) may have a relevant impact,
since slightly negative results for the period may turn positive
thanks to it, as happened in 2014, 2015 and 2017. It was
forecasted as a percentage of services rendered (which was
assumed to be the average of the last two years).
Having negative EBT, IPOLFG just pays a very small amount of
autonomous taxation.
Net income substantial negative results are explained by the
slightly negative EBITDA and the considerable D&A expenses.
OCF, obtained by summing D&A to net income, has been
oscillating around zero and are forecasted to be slightly
negative.
Historical data source: IPOLFG Annual Reports
IPOLFG’s summarized OCF without the new building, 2014-2023
Note that IPOLFG has no interest-bearing debt, reason why Operating Cash-Flow
(OCF) is calculated by summing D&A to net income (and not to EBIT). It was
opted to keep the nomenclature used on the company’s financial statements, but
note that all these CFs result in flow to equity. The CFs mentioned as “financial”,
besides not being material, do not reflect financing decisions, reason why they
were presented inside the OCF.
Values in million € 2014 2015 2016 2017 2018E 2019F 2020F 2021F 2022F 2023F
Revenues 113.9  116.2  124.3  131.4  133.5  135.9  138.4  141.0  144.0  147.0  
Operational Expenses (112.8) (117.1) (126.7) (132.2) (135.0) (137.1) (139.6) (142.2) (145.2) (148.3) 
EBITDA 1.1      (0.9)     (2.3)     (0.8)     (1.5)     (1.2)     (1.2)     (1.2)     (1.3)     (1.3)     
Depr. & Amort. (5.3)     (5.8)     (6.1)     (6.6)     (6.3)     (7.0)     (7.5)     (7.6)     (7.6)     (7.2)     
Provisions of the period (1.8)     (1.4)     (0.7)     (0.1)     (0.4)     (0.4)     (0.4)     (0.4)     (0.4)     (0.4)     
EBIT (5.9)     (8.1)     (9.1)     (7.5)     (8.2)     (8.6)     (9.1)     (9.2)     (9.3)     (8.9)     
Financial gains 0.1      0.0      0.0      0.0      0.0      0.0      0.0      0.0      0.0      0.0      
Financial losses (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     
EBT recurrent (5.9)     (8.1)     (9.1)     (7.5)     (8.1)     (8.5)     (9.1)     (9.2)     (9.3)     (8.9)     
Non-recurrent income 2.4      5.2      1.0      2.3      1.7      1.8      1.8      1.9      2.0      2.1      
% services revenues 2% 5% 1% 2% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3%
Non-recurrent expenses (0.5)     (0.9)     (0.1)     (0.2)     (0.5)     (0.5)     (0.5)     (0.5)     (0.5)     (0.6)     
EBT (4.0)     (3.8)     (8.2)     (5.4)     (6.9)     (7.2)     (7.8)     (7.8)     (7.8)     (7.4)     
Corporate income taxes (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     
Net income (4.0)     (3.9)     (8.2)     (5.4)     (6.9)     (7.3)     (7.8)     (7.8)     (7.8)     (7.4)     
OCF 1.2      2.0      (2.2)     1.3      (0.6)     (0.3)     (0.3)     (0.2)     (0.2)     (0.2)     
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3. IPOLFG’s value without the project
After large fluctuations due to non-recurrent events and accounts payable increase 
(now stabilized), maintenance CAPEX is expected to justify ICF of - €6.5M
IPOLFG’s summarized ICF without the new building, 2014-2023
CAPEX and changes in intangible assets:
– The higher CAPEX level in 2018 is mainly explained by investments
(growth CAPEX) in the Bone Marrow Transplant Unit and in the
Immunohemotherapy Service, being reflected in increased Balance Sheet
values for “Buildings” and “Basic Equipment”.
– 2019 is also expected to register high values due to:
▪ Projects in progress (namely with Portugal 2020) to acquire IT
equipment
▪ The obligation of paying €1.5M relative to projects/plans already
developed for the new building (intangible asset). It must be included
in the scenario with no new building, being a sunk cost, since the
payment is independent from the new building being constructed
– Besides the aforementioned cases, CAPEX values reflect mainly maintenance
CAPEX. Thus, without the new building expansion, CAPEX is assumed to be
equal to D&A expenses from 2020 onwards.
Investment in Net Working Capital (NWC):
– IPOLFG has negative NWC, since current liabilities are
higher than current assets.
– In fact, accounts payable to suppliers represent an
important way of financing the operations and have been
increasing tremendously (€63M in 2017 vs. €27M in
2013), explaining the positive CFs in 2014 and 2016.
Further increases are not sustainable and 2018 values
are expected to close in line with 2017. This situation
reflects the insufficient sources that IPOLFG receives
from the government.
– 2017 negative CF of - €7.6M is mainly explained by the
fact that there was a statutory capital increase of
~€12M in 2017, but just subscribed in 2018, implying
the recognition of that amount as other accounts
receivable (current asset) in 2017.
– 2018 negative CF of - €6.2M is mainly explained by the
fact that, due to changes in the accounting methods
used, €10M considered as deferred revenues (current
liability) in 2017 moved to “subsidies” (equity) in 2018.
– From 2020 onwards, with the stabilization of NWC
levels, the investment in NWC will be close to zero.
Values in million € 2014 2015 2016 2017 2018E 2019F 2020F 2021F 2022F 2023F
CAPEX and 
changes in int.
(5.1)     (5.9)     (6.0)     (5.7)     (10.0)   (9.4)     (7.2)     (7.2)     (7.3)     (7.4)     
Inv. in NWC 9.9      (2.1)     10.7    (7.6)     (6.2)     5.3      0.8      0.8      0.9      0.9      
NWC level (22.6)  (20.4)  (31.1)  (23.6)  (17.4)  (22.7)  (23.4)  (24.2)  (25.1)  (26.1)  
ICF 4.8      (8.0)     4.7      (13.3)   (16.2)   (4.1)     (6.4)     (6.4)     (6.4)     (6.5)     
Historical data source: IPOLFG Annual Reports
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3. IPOLFG’s value without the project
Without the implementation of the new building project, the present value of 
IPOLFG’s future FCF is expected to be - €141.6M
IPOLFG’s FCF without the new building, 2014-2023
Free Cash-Flow (FCF):
– The positive FCF in 2014 and 2016 is mainly a consequence of the abnormally positive
CFs from disinvestment in NWC that led to positive ICF (as previously explained). On the
opposite side, the large negative values in 2017 and 2018 are also a consequence of the
explained non-recurrent phenomena with ICF.
– IPOLFG’s FCF tends to be negative, but with values not as large as in 2017/18. It is
predicted that the FCF will be about - €6.7M, from 2020 onwards, in the scenario
with no new building.
Values in million € 2014 2015 2016 2017 2018E 2019F 2020F 2021F 2022F 2023F
OCF 1.2      2.0      (2.2)     1.3      (0.6)     (0.3)     (0.3)     (0.2)     (0.2)     (0.2)     
ICF 4.8      (8.0)     4.7      (13.3)   (16.2)   (4.1)     (6.4)     (6.4)     (6.4)     (6.5)     
FCF = OCF + ICF 6.0      (6.1)     2.5      (12.0)   (16.9)   (4.4)     (6.7)     (6.7)     (6.6)     (6.7)     
Adjust. in Equity 0.5      4.3      (2.6)     12.0    13.5    2.8      6.7      6.7      6.6      6.7      
Changes in cash 6.6      (1.8)     (0.1)     (0.0)     (3.4)     (1.5)     -      -      -      -      
Adjustments in equity:
– Being fully financed with equity, IPOLFG’s
negative FCF has to be compensated by the
investment of more equity into the
company (when existent cash is not enough).
– In fact, there were statutory capital
increases of €5M in 2015 and €12M in 2017.
– According to the projections, due to annual
negative FCF, the Portuguese State will
have to invest, on average, €6.7M of equity
in IPOLFG every year (in the scenario
without the new building). This shows that
IPOLFG’s business is not self-sustainable.
– In alternative to invest money in IPOLFG via
equity increases, the Portuguese Government
could increase the NHS revenues stablished
in ACSS contract-programs.
– Starting in 2019 and considering a perpetuity value from 2031 onwards, all the estimated future FCF of IPOLFG without the new building
were discounted to the present moment (i.e., January 2019th), using as discount rate IPOLFG’s estimated cost of equity of 4.73% (see
page 30).
– Thus, a negative present value (PV) of - €141.6M was obtained, corresponding to the “firm’s financial value” without the project. This
means that, without the new building, the State would need to invest €141.6M in IPOLFG, in PV terms, to finance its operations.
Historical data source: IPOLFG Annual Reports
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Rationale for the expected impact of the new building on IPOLFG’s outpatient segment
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The number of standard patients is expected to rapidly increase 15% as a result of 
the increased capacity, which will reduce waiting lists and cause a substitution effect
4. IPOLFG’s value with the project
New building: immediate capacity increase of +15% (but with potential for
more than 20%) for the outpatient segment, excluding radiotherapy.
It is believed that the 15% capacity increase for outpatient medicine will
approximately correspond to a 15% increase in the quantity of outpatient
medical services rendered (measured in number of standard patients).
+15% capacity 
increase
15% increase 
in # standard 
patients
IPOLFG has substantial waiting lists, with high average waiting time
(AWT): in 2017, there were 7421 new patients entering IPOLFG’s
Surgery Waiting List (+19% than in 2016) and the AWT was 109
days.* With the extra capacity, people currently waiting will be
converted into patients, increasing the number of patients.
Patients currently treated in the oncology department of non-
specialized hospitals are expected to move to IPOLFG, once there is
capacity available (“substitution effect” reflecting trend for hospitals
specialization). This includes a “substitution effect” between private
and public hospitals, for which waiting lines (that will decrease in
IPOLFG with the new building) and services quality (that will
increase in IPOLFG) are important factors (Dardanoni, et. al., 2018).
Waiting lists
“Substitution 
Effect”
Since extra production has been compensated by ACSS via contract-
program addenda, it is believed that ACSS will remunerate the additional
production.
15% increase in # 
standard patients 
remunerated
– The impact on revenues is obtained by
multiplying the new number of
standard patients by ACSS reference
price (which does not change
relatively to the one in the scenario
without the new building) – page 24.
– The impact on costs is obtained by
multiplying the new number of
standard patients by the costs per
standard patient – page 26.
▪ Additional cost savings and
impacts of the change in the
outpatient/inpatient ratio are
considered – pages 25 and 26.
– Given the lack of strong support (both
empirical and from literature review)
for the fact that the increase in the
number of standard patients will
match capacity increase, a sensitivity
analysis was conducted (later
presented).
(1) (1)
* Sources: IPOLFG 2017 Annual Report and 
Ministry of Health (NHS average waiting time)
4.3 4.5 4.6 4.7 5.6 7.5 7.7 7.9 8.1
2.7 2.7 2.8 2.8 3
3.4 3.5 3.6 3.7
16 16.2 16.5 16.8
18.1
20.2 20.8 21.5 22.1
2.4 2.4 2.5 2.5
2.7
3 3.1
3.2 3.3
13.7 13.9 14.2 14.4
15.5
17.3 17.8
18.4 18.9
24.3 24.7 25.1
25.6
27.4
30.7 31.6
32.6 33.663.4 64.4 65.7
66.8
72.3
82.1
84.5
87.2
89.7
2018E 2019F 2020F 2021F 2022F 2023F 2024F 2025F 2026F
Breakdown of the sources of revenues (m€) that are 
affected by the project (2018-2026)
Other Op. Income Non-NHS NHS addendum
NHS Day Hospital NHS Outpatient DRG NHS Consultations
24
4. IPOLFG’s value with the project
Revenues from the areas affected by the new building are expected to grow 22%* 
from 2021 to 2023, mainly due to the capacity shift, and 3% per year thereafter
– The new building is expected to start operating in the
beginning of 2022.
– The 15% increase in the number of standard patients is
assumed to be progressive over two years: 5% increase in
2022 and the remaining in 2023.
– From 2024 onwards, the number of standard patients is
assumed to rise at the annual growth rate of cancer incident
cases in Portugal (~1%; source: IARC).
– Moreover, revenues are also positively affected by inflation (as it
was the case without the new building).
– Thus, there is a positive shift in 2022 and especially in 2023 for
all sources of revenues, followed by a constant growth of ~3%
from 2024 onwards (2.1% inflation, 1% cancer incidence).
– A particular case is the one of other operating income, which
includes financing for research activities.
– With the large increase in the resources allocated to research
(new Research Center with 2000 m2 versus the current 450
m2), IPOLFG predicts that financing will rise from ~€1M to €3M
(again, it is assumed a progressive increase in 2022 and 2023).
* Overall revenues (including areas not affected by the project), presented
in page 27, only grow 13.3% from 2021 to 2023, and not 22%.
Historical data 
source: IPOLFG 
Annual Reports
Miscellaneous 
Costs
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In 2022, costs savings around €1.3M are expected, mainly due to the end of 
containers’ rents, fewer maintenance expenses and reduction in outsourced services
4. IPOLFG’s value with the project
Rents
2018 Budget  
(k €)
Savings (%) w/ 
new building
Savings (k €) w/ 
new building
Maintenance
Outsourced 
CDT*
Outsourced 
surgeries
Electricity
Gas, heating, 
others
Fuels
Cleaning and 
comfort
Surveillance 
and security
210
3237
824
18
1544
587
20
1653
423
100%
15%
90%
90%
10%
5%
50%
Increase 15%
Increase 15%
210
486
742
16
154
29
10
Increase 248
Increase 63
Rationale
Stop renting containers
Less need for repair (new equipment);
More efficient maintenance (single building)
Currently, some patients are sent to other hospitals due 
to lack of capacity and implied costs are supported. With 
the increase in the installed capacity, this production 
will be in house
Nearly zero energy building (NZEB), with renewable 
energy (solar panels), will imply higher energy 
efficiency and savings
Transportation costs with patients from one building to 
the other will fall thanks to a single building
Increased area will imply higher fixed costs
TOTAL 8516 16% 1335 Sum of all the previous savings/increases
* CDT: Complementary 
Diagnosis TechniquesThese costs were the ones requiring a separated analysis, given specific savings or fixed costs increase with the new building. All the other
costs are calculated by multiplying the cost per standard patient by the new number of standard patients, as presented in the next page
(i.e., the impact is fully captured by the variation in the driver used, the number of standard patients). Source: IPOLFG
4. IPOLFG’s value with the project
Despite the mentioned savings, costs will grow 13.5% from 2021 to 2023, due to 
higher quantities and outpatient high cost of sales, and 3% per year thereafter
52 53 54 57 63 65 67 69
29 29 30 30
32 33 34 35
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148
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Costs (m€) breakdown per type, 2019-2026Costs per standard patient (€), 2019-2026
53
32
64
30
-11
3
Outpatient excl.
radio.
Inpatient
Outpatient vs. Inpatient
profitability analysis based 
on 2017 values (m€)
Revenues Costs EBITDA
– Proportionally, outpatient medical
services (excluding radiotherapy)
have higher costs than inpatient
medicine (namely cost of sales).
– Consequently, upon the increase of
the outpatient segment with the
new building, the necessary
adjustments to the overall costs
per standard patient (for each
type) were done.
– Since outpatient medical services have much higher
cost of sales per standard patient than inpatient
medical services, when outpatient weight on IPOLFG’s
overall services increase, cost of sales per standard
patient have a considerable shift, achieving €1040 in
2022 and €1095 in 2023. Then, it continues to rise at
the inflation rate.
– For miscellaneous and personnel costs, this adjustment
is meaningless, because outpatient and inpatient have
approximately the same costs per standard patient.
They also rise at the inflation rate.
– In 2022, miscellaneous costs increase is offset
by the €1.3M savings presented in the previous
page.
– In 2022 and 2023, there is also an extra increase
in Research and Education personnel costs, in
line with the previous analyzed increase in
financing for research activities.
– Overall, given the larger quantities, the increase
in costs is very substantial (€161M in 2023 vs.
€142M in 2021).
Source: IPOLFG
Source: IPOLFG 26
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4. IPOLFG’s value with the project
After 2022, when OCF is positive (€0.5M) due to that year’s cost savings, quantities 
increase will amplify IPOLFG’s negative EBITDA, leading to OCF around - €0.8M 
– Revenues and operating expenses summarize both the
areas affected and not affected by the project.
– In 2022, EBITDA improves to - €0.6M, because the
specific costs savings partially offset the increase in
costs caused by larger quantities, i.e., revenues increase
in 2022 is larger than costs’.
– The 10% increase in the number of standard
patients in the outpatient segment (excluding
radiotherapy) that takes place in 2023 (totalizing the
15% shift) results in a worse EBITDA (- €2M). It is not
surprising that costs have risen more than revenues,
knowing that IPOLFG has negative profitability and
that the increased segment (outpatient) is the least
profitable one (compared with inpatient).
– D&A expenses have an overall increase due to the
new building and equipment being depreciated.
▪ The decrease in 2023 results from the end of the
amortization of the €1.5M intangible asset relative
to projects/plans developed for the new building
– Non-recurrent income is assumed to have a value
corresponding to 1.3% of revenues, in line with
historical amounts.
IPOLFG’s summarized OCF with the new building, 2019-2028
With the new building, IPOLFG is expected to have negative OCF about - €0.8M, which
represents a €0.5M decrease compared to the forecasted OCF without the new
building. (In 2022, OCF was exceptionally positive thanks to the analyzed costs savings. However, the
further increase in quantities will more than offset the “fixed” savings that take place in 2022.)
This means that, even excluding the investments required, the increased scale results in
slightly worse operational cash generation.
Values in m€ 2019F 2020F 2021F 2022F 2023F 2024F 2025F 2026F 2027F 2028F
Revenues 135.9  138.4  141.0  148.1  159.8  164.8  169.9  175.0  180.3  185.7  
Operational Expenses (137.1) (139.6) (142.2) (148.8) (161.8) (166.8) (172.0) (177.2) (182.6) (188.1) 
EBITDA (1.2)     (1.2)     (1.2)     (0.6)     (2.0)     (2.1)     (2.1)     (2.2)     (2.3)     (2.4)     
Depr. & Amort. (7.0)     (7.7)     (8.1)     (9.5)     (9.0)     (9.1)     (9.1)     (9.2)     (9.3)     (9.4)     
Provisions of the period (0.4)     (0.4)     (0.4)     (0.4)     (0.4)     (0.4)     (0.4)     (0.4)     (0.4)     (0.4)     
EBIT (8.6)     (9.3)     (9.7)     (10.5)   (11.4)   (11.6)   (11.7)   (11.9)   (12.0)   (12.2)   
Financial gains 0.0      0.0      0.0      0.0      0.0      0.0      0.0      0.0      0.1      0.1      
Financial losses (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     
EBT recurrent (8.5)     (9.3)     (9.7)     (10.4)   (11.4)   (11.5)   (11.7)   (11.8)   (12.0)   (12.2)   
Non-recurrent income 1.8      1.8      1.9      2.0      2.2      2.3      2.5      2.6      2.7      2.9      
% services revenues 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3%
Non-recurrent expenses (0.5)     (0.5)     (0.5)     (0.5)     (0.6)     (0.6)     (0.7)     (0.7)     (0.7)     (0.8)     
EBT (7.2)     (7.9)     (8.3)     (9.0)     (9.8)     (9.8)     (9.9)     (10.0)   (10.0)   (10.1)   
Corporate income taxes (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     (0.0)     
Net income (7.3)     (8.0)     (8.3)     (9.0)     (9.8)     (9.9)     (9.9)     (10.0)   (10.0)   (10.1)   
OCF (0.3)     (0.3)     (0.2)     0.5      (0.8)     (0.8)     (0.8)     (0.8)     (0.8)     (0.7)     
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4. IPOLFG’s value with the project
With the implementation of the new building project, the present value of 
IPOLFG’s future FCF is expected to go from - €141.6M to - €198.4M
IPOLFG’s summarized FCF with the new building, 2019-2028
– The €40M investment in the new building is assumed to be split
in: €8M in the end of 2019 (start of constructions); €16M in 2020
(60% done); €16M in 2021 (100% done). The €5M investment in
new basic equipment is assumed to be done in the end of 2021.
– Until 2026, it is considered that virtually zero maintenance
CAPEX is required for the new building, in line with public works
warranty period (5 years).* From 2027 onwards, maintenance
CAPEX for the new building is assumed to match depreciation.
– Given IPOLFG’s negative NWC, the growth registered each period
will lead to slightly positive investment in NWC CFs (higher in
2023 due to larger scale shift).
– According to the financing plan presented on page 11, IPOLFG will
receive €12M from SUCH, €3M from JMT and €5M form sponsors,
assumed to be split as now shown on the left table (SUCH invests
earlier, since underground floors are the first being constructed).
– To match the timing of the investments, the State should split the
€25M statutory capital increase in €8M in 2020 and €17M in 2021.
* Source: APCMC
The State not only will have to invest the €25M required for the project’s investment, as it will also have to invest extra capital to offset the negative FCF
each period: from 2020 to 2022, the amount required is approximately the same than the one without the new building, but, in steady-state, the State has to
invest €8.7M per year, instead of €6.7M.
Values in m€ 2019F 2020F 2021F 2022F 2023F 2024F 2025F 2026F 2027F 2028F
OCF (0.3)     (0.3)     (0.2)     0.5      (0.8)     (0.8)     (0.8)     (0.8)     (0.8)     (0.7)     
CAPEX and 
changes in int.
(17.4)   (23.2)   (28.2)   (8.4)     (8.5)     (8.5)     (8.6)     (8.7)     (9.5)     (9.6)     
Inv. in NWC 5.4      1.0      1.2      1.6      4.4      1.5      1.6      1.6      1.6      1.7      
NWC level (22.8)  (23.8)  (25.0)  (26.6)  (31.0)  (32.5)  (34.1)  (35.7)  (37.3)  (39.0)  
ICF (12.0)   (22.2)   (27.1)   (6.8)     (4.0)     (7.0)     (7.0)     (7.1)     (7.9)     (7.9)     
FCF without 
financing effects
(12.3)   (22.4)   (27.3)   (6.3)     (4.8)     (7.8)     (7.8)     (7.8)     (8.7)     (8.7)     
SUCH 8.0      4.0      
JMT 1.5      1.5      
Sponsors 2.5      2.5      
FCF w/ financing 
effects
(4.3)     (14.4)   (23.3)   (6.3)     (4.8)     (7.8)     (7.8)     (7.8)     (8.7)     (8.7)     
Adj. in Equity 2.7      14.4    23.3    6.3      4.8      7.8      7.8      7.8      8.7      8.7      
Statutory capital 
increase (project)
-      8.0      17.0    -      -      -      -      -      -      -      
Extra adj. in Equity 2.7      6.4      6.3      6.3      4.8      7.8      7.8      7.8      8.7      8.7      
Changes in cash (1.5)     -      -      -      -      -      -      -      -      -      
Discounting all the estimated future FCF of IPOLFG with the new building to the present moment, using as discount rate IPOLFG’s estimated
cost of equity of 4.73% (see page 30), a negative PV of - €198.4M was obtained, corresponding to the “firm’s financial value” with the project.
This means that, with the new building, the State would need to invest €198.4M in IPOLFG, in PV terms, to finance its operations.
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IPOLFG’s estimated unlevered cost of equity of 4.73% was used to discount 
unlevered CFs, while each financing CF was discounted at a specific rate
5. Discount rates
IPOLFG has no interest-bearing debt, so its cost of capital is equal to its unlevered cost of equity, which
should reflect the operational risk of the business (measured by the unlevered equity beta).
IPOLFG unlevered cost of equity was estimated using CAPM:
– A “risk-free” 1 rate of 1.69% was considered, corresponding to 10-year Portuguese Government
Bonds2, in order to include the country risk and approximately match CFs duration.
– An equity market risk premium (MRP) of 5.5% was used. 3
– IPOLFG’s equity beta, which should correspond to its sector unlevered equity beta, was estimated
as the average unlevered beta of 4 European publicly-traded healthcare companies, selected as the
best proxies (analysis presented in Att. 2).
▪ The obtained value of 0.55, although showing that the healthcare sector’s sensitivity to market
fluctuations is little, should still be seen as an upper bound for IPOLFG, since: (i) the oncology
business is expected to have slightly less risk than general medical services; (ii) public
healthcare services are also expected to fluctuate less than private ones. Despite this
limitations, CAPM was still considered a better approach than alternatives (as simply using an
hurdle rate for public projects). In fact, the operational risk of the specific business must be
taken into account.
– Given the three values mentioned, an unlevered cost of equity of 4.73% was obtained for
IPOLFG and used to discount all the project’s FCFs except the ones referring to the side financing.
A sensitivity analysis was conducted, considering the impact of smaller unlevered betas, as
presented in Att. 2.
1. As referred, it has a long-term maturity and includes the country risk; consequently it is not actually a pure risk-free rate.
2. Source: Bloomberg. 3. Source: KPMG 2018 Equity Market Risk Premium – Research Summary.
Discount rate for FCF (excl. side financing): IPOLFG’s estimated 4.73% cost of equity
JMT: considered its cost of debt2 of
0.75%, since it reflects the risk of JMT
not complying with the delivery of the
expected amount.
SUCH: considered a 0% rate: there is
a signed protocol defining that the
risk is fully supported by SUCH (it will
deal directly with the constructors
and pay the necessary amount, even if
higher than the expected €12M).
Sponsors: considered a 7.68% rate,
obtained by summing a spread of 8%
to the 1-year Portuguese Government
Bond2 of -0.32%. The 8% spread
reflects an assumed probability of
20% of not contributing the full
amount and a 40% loss for that case,
thus reflecting the uncertainty relative
to sponsors financing.
Discount rates for financing CFs
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6.1. Project’s NPV
The project’s NPV is - €56.7M considering the perpetuity value. If thinking only until 
2030, treating 48k additional standard patients implies a negative NPV of  - €26.3M
IPOLFG’s summarized project’s incremental FCF (2019-2028) – The project’s incremental CFs are obtained as the difference
between the respective CFs with the new building and the CFs
without the new building. Thus, the results presented are a
summary of all the analyses previously conducted.
– The €45M investment and respective financing are split from 2019
to 2021, resulting in large negative incremental FCF in 2020/21.
– In 2022, FCF is positive thanks to costs savings related with the
new building shift (starting to operate in 2022).
– In 2023, it is expected the largest increase in quantities (10%,
against 5% in 2022). Since IPOLFG’s has negative NWC levels, this
shift originates large positive CFs relative to (dis)investment in
NWC, explaining the positive FCF of €1.9M.
– From 2027 onwards (when maintenance CAPEX with the new
building is assumed to start), negative incremental FCF of - €2M
are expected for the project, implying that the State has to put
additional €2M in equity per year, compared to the scenario
without the new building.
Considering only until 2030, by deciding to invest in this project, the State needs to
put €550 in equity in IPOLFG per each one of the 48k additional patients treated
- €198.4M
IPOLFG’s value 
w/ the project
- €141.6M
IPOLFG’s value 
w/o the project
- €26.3M
- €30.4M
NPV CFs until 
2030
This project does not only imply a €25M investment for the State; it implies an
additional investment of €31.7M (via IPOLFG’s equity increase), in present value terms
NPV CFs 2030 
onwards 
(perpetuity)
Project NPV = - €56.7M
48k
additional 
standard patients 
treated until 2030
NPV per standard 
patient = - €550
Values in m€ 2019F 2020F 2021F 2022F 2023F 2024F 2025F 2026F 2027F 2028F
Revenues -   -    -    4.2    12.8  14.7  16.7  18.6  20.5  22.6  
Operational Expenses -   -    -    (3.5)  (13.5) (15.4) (17.5) (19.4) (21.4) (23.6) 
EBITDA -   -    -    0.7    (0.7)   (0.7)   (0.8)   (0.8)   (0.9)   (1.0)   
…
OCF -   (0.0)   (0.0)   0.7    (0.6)   (0.6)   (0.6)   (0.7)   (0.7)   (0.7)   
ICF (7.9)  (15.7) (20.7) (0.4)  2.4    (0.5)   (0.5)   (0.5)   (1.3)   (1.3)   
Financing effects 8.0    8.0    4.0    -   -    -    -    -    -    -    
FCF w/ financing 
effects
0.1    (7.7)   (16.7) 0.3    1.9    (1.1)   (1.1)   (1.2)   (2.0)   (2.0)   
Adj. in Equity (0.1)  7.7    16.7  (0.3)  (1.9)   1.1    1.1    1.2    2.0    2.0    
Statutory capital 
increase (project)
-   8.0    17.0  -   -    -    -    -    -    -    
Extra adj. in Equity (0.1)  (0.3)   (0.3)   (0.3)  (1.9)   1.1    1.1    1.2    2.0    2.0    
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6.2. Sensitivity and scenario analyses
Although always negative, the project’s NPV is considerably sensitive to some key 
drivers: possible scenarios show a range between - €18.2M and - €76.9M
-76.9
-18.2
-43
-29.9
-22.3
-66
-47.5
-56.7
Project NPV (million €)
-677
-457
-675
-907
-1173
-593
-508
-550
Project NPV per
standard patient (€)
Given the uncertainty regarding the
magnitude of some savings presented
on page 25, an optimistic case of €1.7M
savings and a pessimistic one of only
€1M savings were considered. Given the
perdurability of this ~0.3M shift in all
future years, there is a material impact
of approximately €10M on the
project’s NPV.
Inputs/Drivers for Scenario Analysis Base Case Scenario 1 Scenario 2
Cost of sales per st. patient (€) 934         924          942          
Misc. costs per st. patient (€) 513         508          518          
Personnel costs per st. patient (€) 1,008      998          1,018       
Increase in # standard patients 15.0% 10.0% 15.0%
Non-recurrent income as % of revenues 1.3% 2.0% 1.0%
Savings with new building (m€) 1.3          1.7           1.0           
It is questionable if production will increase as much as
capacity. Besides the base case (15%), smaller increases were
considered: 10%; 5%; no shift, growing only at the cancer
incidence growth rate, as in the following years. Since IPOLFG
has negative profitability, less quantities actually means
less negative NPV. However, here it is particular important to
analyze NPV per patient figures: due to fixed expenses (namely
the initial investment), if the number of standard patients is
smaller, the NPV per patient is substantially more negative.
When allowing for small changes in
several drivers at the same time (as
the ones on the table), NPV may
vary a lot, showing how sensitive
some assumptions are. In the most
optimistic case, the project has a
NPV of - €18.2M, meaning that, from
the initial €25M that the State puts,
it still recovers €6.8M, in PV terms.
▪ Base case
▪ Sensitivity to costs savings
▪ Sensitivity to number of standard patients increase
▪ Scenario Analysis
No shift
€1.7M
€1.0M
5%
10%
(1)
(2)
Case:
Base
Sensitivity to
the €1.3M costs savings
Sensitivity to the estimated 15% increase in the number 
of standard patients
Scenario analysis
If ACSS would not increase the contracted revenues in the necessary amount to fully compensate production increase, the NPV would decrease ~€7M for each 1% of
production not remunerated (since, for that part, only costs would increase). Although this risk must be taken into account, it is considered unlikely, because: (i)
contract-programs addenda had make an effort to match actual quantities produced; (ii) if the State approves the project, it should be implied that extra
production needs to be remunerated.
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Financial 
results:
- €56.7M 
NPV
Non-
financial 
benefits
(social 
welfare)
Other 
suggestions
Main risks
– Decrease the number of patients in waiting lists and the average waiting time.
– Increase IPOLFG’s service quality (e.g.: stop using containers; avoid outpatients moving
from one building to the other).
– Increase research activities (potential new findings about oncology and techniques used).
– By assuring higher capacity for IPOLFG, the State has more control over the services
provided than if leaving it to privates’ care, also guaranteeing that all patients are treated.
– Demand may not match IPOLFG’s increased capacity, which would imply a larger negative
NPV per patient.
– Uncertainty about costs savings, mainly energy efficiency gains.
– Deviations in the investment amount: the State will have to support every euro in addition
to the €45M predicted (except for the underground floors, whose risk is born by SUCH).
– Financing: there is uncertainty about JMT and especially about the sponsors financing. If they
do not put the expected amount, the State will have to cover the difference.
6.3. Final remarks
This report provides the necessary financial information for the competent 
authorities to weigh the project’s financial cost against its benefits and decide
– IPOLFG can try to improve its operational efficiency by reducing costs. Otherwise, every
time IPOLFG increases its scale, ceteris paribus, negative results in absolute terms will be
even larger.
– The State should revise ACSS reference price stablished on contract-programs, since it
seems to be insufficient for IPOLFG reality. It should analyze if it is preferable to give more
money via revenues or via capital increases.
– The NPV is extremely important for IPOLFG and the State to know how much the project
will cost, but this is not a “typical project” where the NPV is a (binding) decision rule.
Despite the negative NPV, the State may want to approve the project, given the increase
in social welfare. It is a decision about spending money to provide public oncology
services to more patients. Ultimately, it is a political decision.
To study the possibility of the State
using more efficient hospitals,
namely private ones, to provide more
oncology services, instead of
increasing IPOLFG’s capacity.
Estimate by how much waiting lists
and average waiting time are going
to decrease.
Based on Energy Performance
Certificates (IPOLFG still does not
know the one for the new building),
estimate more accurately the energy
savings.
Deeper study about sponsors
financing.
Benchmarking analysis and
operational plan implementation.
Revision of State financing: revenues
via contract-program vs. equity.
Further Analyses
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Attachment 1: Representation of IPOLFG’s campus and plan for the new building
7. Appendices
Picture A: Representation of IPOLFG’s infrastructures, with 15 disperse
buildings. The new building is planned to be constructed on the red area.
Source: IPO website.
Picture B: Fictitious representation of IPOLFG’s
new ambulatory building.
Source: “IPOLFG New Ambulatory Building
Functional Program”.
Healthcare 
selected firms
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Attachment 2: Estimation of a proxy for IPOLFG’s unlevered equity beta
7. Appendices
SPI LN Equity
Levered 
equity beta1
D/E
Ratio1
Statutory
tax rate1
MCOVB SS 
Equity
CAPIO SS 
Equity
RHK GR Equity
0.48
0.76
0.81
0.55
0.50
0.13
0.67
0.03
19.25%
22.00%
22.00%
29.79%
Description
Spire Healthcare Group PLC (UK) provides a wide variety of private 
healthcare services in the UK
Medicover AB (Sweden) provides healthcare and diagnostic services 
worldwide (ambulatory clinics, hospitals, laboratories)
AVERAGE
Cost of 
debt1
Beta
debt
2.15%
0.80%
1.76%
0.24%
0.35
0.10
0.28
0.00
Unlevered 
equity beta
0.42
0.68
0.58
0.53
Capio AB (Sweden) provides medical, surgical and psychiatric 
healthcare services in Sweden, Norway, France, Germany
Rhoen-Klinikum AG (Germany) operates general, rehabilitation, and 
emergency healthcare facilities (inpatient and outpatient) in Germany
0.63 0.33 24.61% 1.24% 0.18 0.55 The average unlevered equity beta was the value used for IPOLFG
1. Source: Bloomberg. 2. Source: KPMG 2018 Equity Market Risk Premium – Research Summary.
– Each company’s levered equity beta was obtained by regressing the firm’s weekly excess returns on the market’s weekly excess returns, from
12/10/2013 to 11/10/2018. The STOXX Europe 600 Index was used as proxy for the market, since the selected companies are European. 1
– Each company’s beta debt (necessary to calculate the respective unlevered equity beta) was calculated using CAPM, considering the presented
cost of debt, a MRP of 5.5%2 and a risk-free rate of 0.25% (corresponding to 10-year German Government Bonds1).
– Each company’s unlevered equity beta was computed using Modigliani-Miller equation, considering the respective values presented for the
levered equity beta, the beta debt, the D/E ratio and the statutory tax rate.
– Unlevered beta sensitivity analysis: due to the reasons mentioned in the main report, values of unlevered beta smaller than the obtained
average should be tested. In this particular case, since FCF is negative, a smaller unlevered beta (resulting in a smaller discount rate) leads to
larger negative results (i.e., worse NPV, contrary to what happens for positive NPVs). Thus, the project’s NPV would be - €69M for a 0.405
unlevered beta, - €88M for a 0.270 unlevered beta, and - €203M for an extreme bound with an unlevered beta of zero (which is necessarily not
true, since, among other reasons, ACSS budget, and consequently IPOLFG’s revenues, reacts to market economic fluctuations).
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